DDInter915 DDInter1882
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
A macrolide antibiotic that is similar to erythromycin.
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Loratadine
Loratadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Loratadine
Loratadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salmeterol
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Loratadine (Compound) and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Troleandomycin
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loratadine (Compound) and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Troleandomycin
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salmeterol (Compound) and Salmeterol may lead to a major life threatening interaction when taken with Troleandomycin
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may lead to a major life threatening interaction when taken with Troleandomycin
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Troleandomycin
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin